文献速递血管炎

2022年ACR/EULAR巨细胞动脉炎分类标准在常规临床疑似巨细胞动脉炎患者中的诊断性能

Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care.
PubMed 文献 · RMD Open · 2023-01-01

多中心回顾性观察研究纳入319例疑似巨细胞动脉炎患者(188例病例、131例对照),以随访6个月后临床确诊为金标准,评估2022年ACR/EULAR分类标准的诊断性能。总体敏感性92.6%、特异性71.8%,AUC 0.928(95%CI 0.899至0.957);孤立性大血管型敏感性62.2%,活检证实的巨细胞动脉炎敏感性100%。

要点

  • 2022年ACR/EULAR分类标准总体敏感性92.6%、特异性71.8%,AUC 0.928(95%CI 0.899至0.957)。
  • 孤立性大血管型敏感性62.2%、特异性71.8%,AUC 0.691(95%CI 0.592至0.790)。
  • 1990年ACR标准总体敏感性53.2%、特异性80.2%。

核心结论

  • 2022年ACR/EULAR巨细胞动脉炎分类标准在常规诊疗的疑似巨细胞动脉炎患者中显示出足够的诊断准确性,且在所有患者亚组中较1990年ACR分类标准的敏感性和特异性均有改善。

研究设计与样本

  • 多中心回顾性观察研究,纳入转诊至两个超声快速通道诊所的319例患者(188例巨细胞动脉炎病例、131例对照),平均年龄76岁、女性58.9%。
  • 以随访6个月后临床确诊为巨细胞动脉炎诊断金标准;所有患者基线接受颞动脉及颅外动脉(颈动脉、锁骨下动脉和腋动脉)超声检查,氟脱氧葡萄糖-正电子发射断层扫描/CT按标准临床医生标准进行。

主要发现

  • 2022年EULAR/ACR巨细胞动脉炎分类标准总体敏感性92.6%、特异性71.8%,以巨细胞动脉炎临床诊断为外部标准,AUC为0.928(95%CI 0.899至0.957)。
  • 孤立性大血管型巨细胞动脉炎敏感性62.2%、特异性71.8%,AUC 0.691(95%CI 0.592至0.790)。
  • 活检证实的巨细胞动脉炎敏感性100%、特异性71.8%,AUC 0.989(95%CI 0.976至1)。
  • 1990年ACR标准总体敏感性53.2%、特异性80.2%。

关键数值与推荐

  • 2022年ACR/EULAR巨细胞动脉炎分类标准总体敏感性92.6%、特异性71.8%,AUC 0.928(95%CI 0.899至0.957)。
  • 孤立性大血管型敏感性62.2%、特异性71.8%,AUC 0.691(95%CI 0.592至0.790)。
  • 活检证实的巨细胞动脉炎敏感性100%、特异性71.8%,AUC 0.989(95%CI 0.976至1)。
  • 1990年ACR标准总体敏感性53.2%、特异性80.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the performance of the new 2022 American College of Rheumatology (ACR)/EULAR giant cell arteritis (GCA) classification criteria for diagnosis in routine clinical care. METHODS: Multicentric retrospective observational study of patients referred to two ultrasound (US) fast track clinics. Patients with GCA were compared with unselected controls with suspected GCA. The gold standard for GCA diagnosis has been clinical confirmation after 6 months of follow-up. All patients underwent an US exam of temporal and extracranial arteries (carotid, subclavian and axillary) at baseline. Fluorodeoxyglucose-positron emission tomography/CT was performed according to standard clinician criteria. The performance of the new 2022 ACR/EULAR GCA classification criteria was evaluated in all patients with GCA across different subsets of the disease. RESULTS: A total of 319 patients (188 cases, 131 controls) were included for analysis (mean age 76 years, 58.9% females). Overall, the 2022 EULAR/ACR GCA classification criteria had a sensitivity of 92.6% and a specificity of 71.8%, using GCA clinical diagnosis as external criterion and the area under the curve (AUC) was 0.928 (95% CI 0.899 to 0.957). Isolated large vessel-GCA showed a sensitivity of 62.2% and a specificity of 71.8% (AUC 0.691 (0.592 to 0.790)), while biopsy-proven GCA showed a sensitivity of 100% and a specificity of 71.8% (AUC 0.989 (0.976 to 1)). Overall sensitivity and specificity of the 1990 ACR criteria was 53.2% and 80.2%, respectively. CONCLUSIONS: The new 2022 ACR/EULAR GCA classification criteria showed adequate diagnostic accuracy in patients with suspected GCA under routine care, and an improvement on the sensitivity and specificity of the 1990 ACR classification criteria in all patient subsets.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Molina-Collada J, Castrejón I, Monjo I, et al. Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care. RMD Open. 2023. PMID: 37094980. doi:10.1136/rmdopen-2022-002970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。